The National Pharmacology and Nutrition Institute of Hungary (OGYÉI) has registered the Russian anti-COVID-19 vaccine Sputnik V, reports Russian Direct Investment Fund (RDIF)
Hungary was the first EU state which officially authorized the use of the Sputnik V vaccine on its territory. The marketing authorization of this vaccine was carried out as part of an accelerated procedure (emergency use authorization) based on data of Sputnik V clinical researches in Russia and a comprehensive expert assessment of the drug.
Within the similar procedure, Sputnik V was previously authorized in Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Russia and Belarus.
“Hungary is the first EU country that assessed benefits of the Russian Sputnik V vaccine and approved its use on its territory. This is the most important decision that demonstrates a high assessment of the vaccine safety and effectiveness”, said Kirill Dmitriev, CEO of the RDIF.
Earlier, deputy director of the Gamalei Epidemiology and Microbiology National Research of the Ministry of Health of Russia Denis Logunov, said that the Sputnik V vaccine is safe, due to its basis – the adenovirus vector, which is not able to reproduce, reports RIA Novosti. He noted that adenoviruses have been living with a person for a long time. The vaccine uses not the adenoviruses themselves, but their vectors – viruses without responsible areas of reproduction.
